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Summary CA242 has been proved to be useful in the diagnosis of pancreatic cancer. The aim of the present
study was to clarify the mechanisms contributing to the high specificity of CA242 as compared with CA19-9
resulting from scarce serum elevation of this antigen in patients with chronic pancreatitis by correlating serum
levels and endoscopic retrograde choledocho-pancreatography (ERCP) findings and by immunohistochemical
analysis. Serum CA19-9 levels were significantly elevated in patients with calcification and with main pancreatic
duct (MPD) stenosis or obstruction. On the other hand, serum CA242 levels showed no significant elevation in
patients with such factors. Even though such pathological conditions were considered to lead to the stagnation
of pancreatic juice, serum CA242 levels seemed to be less affected than serum CA19-9 levels.
Immunohistochemical studies of chronic pancreatitis tissues revealed that CA242 was expressed less frequently
and less intensely than CA19-9, and the difference in expression was more prominent in the centroacinar cells
and terminal ductules. From the results of the present study, it is conceivable that CA242 is less influenced by
the stagnation of the pancreatic juice than CA19-9 because of the low levels of expression in ductal systems,
which results in the release of this antigen into the circulation in lower amounts than that of CA19-9.
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In a previous study, we reported that the new tumour marker
CA242 showed sensitivity similar to that of CAl9-9 for
overall cases and early cases (stage I tumour) of pancreatic
cancer, and was only slightly and infrequently elevated in the
sera of patients with benign diseases, as also reported by
others (Lindholm et al., 1985; Kawa et al., 1994a; Johansson
et al., 1991a; Nilsson et al., 1992; Pasanen et al., 1992; Banfi
et al., 1993; Rothlin et al., 1993; Haglund et al., 1994). These
findings suggest the usefulness of this marker for screening
pancreatic cancer patients on their first hospital visit.
Although the epitope recognised by the monoclonal anti-
body (MAb) C242 used in this assay system has not yet been
fully elucidated, C242 showed unique characteristics in that it
has no reactivity to sialosyl-fucosyl-lactotetraose (sialyl
Lewisa) or sialosyl-lactotetraose (sialyl Lewisc) (Johanson et
al., 1991b; Kuusela et al., 1991), whereas MAbs for
established tumour markers useful for diagnosis of pancrea-
tic cancer were confirmed to have reactivities to either or
both structures; NS19-9 for sialyl Lewisa, DUPAN-2 MAb
for sialyl Lewisc, C50 and Span-1 MAb mainly for sialyl
Lewisa and in part for sialyl Lewisc (Magnani et al., 1982;
Nilsson et al., 1985; Kawa et al., 1994b).
The differentiation of pancreatic cancer from chronic
pancreatitis is sometimes difficult clinically at the time of
admission, and false positivity in tumour markers leads to
further imaging tests, which is wasteful of these facilities. As
reported previously, the specificity of CA242 (86%) was
higher than that of CA19-9 (76%) calculated from the results
of chronic pancreatitis, using cut-off values of 30 and
37 U ml-1 (CA242 and CA19-9, respectively) both of which
provided optimal discrimination between pancreatic cancer
and benign diseases (Del Villano et al., 1983; Kawa et al.,
1994a) and favourable results in detecting Stage I pancreatic
cancer (Kawa et al., 1994a). Using cut-off values of 35 and
80 U ml-' (CA242 and CA19-9 respectively) corresponding
to the 90% of specificity level for chronic pancreatitis,
elevated CA242 and CA19-9 levels were seen in 78% and
72% of the patients with pancreatic cancer respectively
(Kawa et al., 1994a). These results indicate that this marker
will provide a new tool for the discrimination of both
conditions. However, it is not certain why CA242 has an
advantage over CA19-9 in its higher specificity. Tissue
expression of CA242 was reported to be similar to that of
CA19-9, in which both antigens were expressed mainly in the
apical border of ductal cells and luminal content, but also to
some extent intracellularly (Haglund et al., 1989), indicating
that CA242 was secreted into the pancreatic juice. As
reported for CA19-9, which is expressed at high levels in
epithelial cells of the bile duct system (Arends et al., 1983;
Kobayashi et al., 1991), it could be possible from its similar
tissue localisation that CA242 is also secreted into the bile
juice. Accordingly, serum elevation of both markers in
patients with chronic pancreatitis may be caused by one of
the following mechanisms: (1) stagnation of the pancreatic
juice; (2) necrosis of pancreatic tissue; and (3) cholestasis.
These pathological conditions can be to some extent assessed
by endoscopic retrograde choledocho-pancreatography
(ERCP) and computed tomography (CT) findings. Stagna-
tion of the pancreatic juice can be caused by the stenosis or
obstruction of the main pancreatic duct (MPD) and
pancreatic stones and necrosis of the pancreatic tissue leads
to the formation of pseudocysts. Extrahepatic cholestasis is
related to stenosis of the intrapancreatic bile duct. The aim of
the present study was to clarify the mechanisms operating in
the scarce serum elevation of CA242 as compared with
CA19-9 in patients with chronic pancreatitis by correlating
serum levels with ERCP and CT findings and by
immunohistochemical analysis.
Materials and methods
Patients
Sera and imaging tests were analysed for 70 patients with
chronic pancreatitis in Shinshu University Hospital and its
affiliated hospitals. Serum samples were collected within the 2
weeks before ERCP, in which period patients were confirmed
to be free from acute attack, and stored at -80°C before use.
The diagnosis of chronic pancreatitis was confirmed by
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1995fulfilment of at least one of the following criteria proposed by
the Japanese Society of Gastroenterology: (a) significant
changes in the pancreatogram as shown by ERCP; (b)
calcification of the pancreas; (c) significant impairment of
exocrine function as shown by pancreozymin-secretin test or
secretin test; and (d) histological confirmation at laparotomy.
Patients comprised those with alcoholic (n =47) and
idiopathic (n =23) pancreatitis. All patients were checked
for the presence or absence of complications such as diabetes
mellitus, benign liver disease and renal failure, which have
been reported to influence the serum levels of tumour
markers.
Assays
Serum CA242 level was measured by a dissociation-enhanced
lanthanide fluoroimmunoassay (DELFIA) (Wallac Oy,
Turku, Finland), in which monoclonal antibodies C241 and
C242 were used as catcher and tracer antibodies respectively.
For CA19-9, radioimmunoassay (RIA) kit (Centocor,
Pennsylvania, USA) was used. All assays were performed
according to the manufacturers' instructions.
Assessment of ERCP and CTfindings
ERCP and CT tests were performed in all patients. All ERCP
findings were assessed with respect to the presence or absence
of the following pathological conditions, which may influence
serum elevation of tumour markers. Stagnation of pancreatic
juice is related to pancreatic stones (Figure la) and
obstruction or stenosis of the main pancreatic duct (Figure
lb). Necrosis of pancreatic tissue is related to the formation
of pseudocysts. Extrahepatic cholestasis is related to
intrapancreatic bile duct stenosis (Figure 1c). The presence
of pancreatic stones and the pseudocysts were also assessed
by CT findings.
Immunohistochemical study
Immunostaining was performed on pancreatic tissues
obtained at surgery or autopsy from 12 patients with
chronic pancreatitis by means of the conventional indirect
immunoperoxidase staining method. After deparaffinisation,
tissue samples were treated with 0.4% pepsin (2500 FIP-
U g-'; Merck, Darmstadt, Germany) in 0.01 N HCI for 1 h
at 37°C and incubated in 0.5% hydrogen peroxide in
methanol for 30 min to block endogenous peroxidase
according to the method reported previously (Haglund et
al., 1989). Tissue samples were then incubated with non-
immune goat serum, diluted 1:20 and then reacted with the
respective monoclonal antibody, C242 (1:50) and NS19-9
antibody (adjusted for immunostaining, Centocor) at 4°C
overnight. Peroxidase-labelled anti-mouse IgM/IgG (1: 100,
Tago, Burlingame, CA, USA) was reacted as the second
antibody for 60 min at room temperature. Each step was
followed by washing in phosphate-buffered saline (PBS).
Finally, sections were incubated with diaminobenzidine and
hydrogen peroxide, and then counterstained with methyl
green. An arbitrary scoring of staining intensity using + or
+ + was used for the various duct systems, centroacinar cells
and terminal ductules, small ducts (intralobular and
interlobular duct), large ducts (branch duct and MPD) and
hyperplasia. In addition, the localisation of each antigen was
also checked in small and large ducts to examine whether
disturbed antigen polarity was associated with the elevation
of serum levels.
Statistics
Descriptive statistics of serum levels are presented as median,
25th and 75th percentiles for patients with or without each
pathological condition. Statistical analyses of differences
between serum levels of positive and negative cases for each
pathological condition were performed using Mann-Whitney
U-test and Welch t-test.
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Figure 1 Assessment of the ERCP findings that may be related
to the elevation of tumour markers. (a) Calcification. (b) MPD
stenosis. (c) Intrapancreatic bile duct stenosis.
Table I Serum levels of cancer-associated antigens in patients with
chronic pancreatitis with respect to each ERCP finding
CA242 CA19-9
(Umr,) (U mrl)
Calcification (+) n=30 31.2+ 58.8 67.4± 179.1
n=40 13.0±9.6 26.7± 59.9
MPD stenosis (+) n= 18 31.4± 71.3 104.4+237 6
or obstruction (-) n=49 17.2±20.5 23.8+32.3 }
Pseudocyst (+)n= 15 22.9+ 24.5 53.4+91.7
n=55 20.2+43.2 41.6+ 134.7
CBD stenosis (+) n= 15 19.3 ±21.5 32.0± 34.7
n=46 22.5+47.5 54.0+153.9
All values are shown by mean s.d. Welch t-test: P<0.05. MPD,
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Results
Effects of complications
Of 70 cases, 14 were complicated with overt diabetes mellitus.
No significant differences in serum levels for each marker
were found between patients with and without diabetes
mellitus (data not shown). With regard to other complica-
tions, we found three patients with benign liver diseases and
no patients with renal failure. Because of the small number of
patients, these complications had no effects on the serum
elevation ofeach marker in the patient groups enrolled in this
study.
Correlation between serum levels and each ERCPfinding
For CA19-9, the serum level was likely to be affected by
pathological conditions related to stagnation of pancreatic
juice, and a significant difference was found between patients
with and without MPD stenosis or obstruction and with and
without calcification by Mann-Whitney U-test (Figure 2).
The presence of pseudocysts and CBD stenosis seemed to
exert no effect on the serum level of CA19-9. For CA242, no
significant differences in serum levels were found between
patients with and without these factors. Analysis with Welch
t-test showed almost the same results, the only significant
difference of serum CA19-9 levels being found between
patients with and without MPD stenosis or obstruction
(Table I).
Immunostaining of each marker
The frequency and intensity of the expression of each marker
in 12 chronic pancreatitis tissues are summarised in Figure
3a. CA242 was expressed less at various levels of the duct
systems as compared with CA19-9 (sialyl Lewisa). The
difference in the expression of these markers was marked,
especially in the centroacinar cells and the terminal ductules
in some cases (Figure 4). However, CA242 was highly
expressed in hyperplasia and the large ducts of tissues of
some patients with ERCP findings related to stagnation of
pancreatic juice. The localisation ofeach antigen in small and
large ducts was also compared to examine whether the
elevation of serum level was influenced by disturbed antigen
polarity (Figure 3b). The disturbed antigen polarity, i.e.
cytoplasmic staining, was infrequently seen in the expression
of both CA242 and CA19-9.
CA242
Discussion
In chronic pancreatitis, the mechanisms operating in the false
elevation of serum tumour marker are classified into two
categories: the structural changes occurring in the pancreas
and complications that are not directly related to these
structural changes. Benign liver diseases (chronic hepatitis
and liver cirrhosis) and diabetes mellitus are major
complications leading to the false elevation of conventional
tumour markers in this disease. However, neither condition
exerted any effect on serum elevation of the tumour markers
in the patient groups enrolled in this study. Accordingly our
attention was focused on the structural changes occurring in
the pancreas that were considered to be associated with the
false elevation of serum levels.
The elevation of serum CA242 levels was not affected by
the presence of calcification, MPD stenosis or obstruction,
pseudocysts or stenosis of the intrapancreatic bile duct,
indicating that these factors had no effects on the serum
elevation of this marker. On the other hand, serum CA19-9
levels were significantly elevated in patients with calcification
and with MPD stenosis or obstruction. While such
pathological conditions were considered to lead to the
stagnation of pancreatic juice, serum CA242 levels seemed
to be less affected by these conditions than serum CA19-9
levels. Immunohistochemical studies revealed that CA242 was
expressed in the cells of various ductal systems less frequently
and less intensely compared with CA19-9, which was more
prominent in the centroacinar cells and terminal ductules.
These findings were in disagreement with those of a previous
report (Haglund et al., 1989), in which the expression of
CA242 was similar to that of CA19-9. From the findings of
the present study, it is conceivable that the small amounts of
CA242 in ductal cells were scarcely affected by stagnation of
pancreatic juice, resulting in the release of this antigen into
the circulation in smaller amounts than CA19-9, which was
found to be extensively expressed.
We found no previous reports concerning the correlation
between serum elevation of tumour marker and the ERP
findings in patients with chronic pancreatitis. CA19-9 levels
of pancreaticjuice were reported to be higher in patients with
calcifications (Tatsuta et al., 1985; Malesci et al., 1987),
indicating that antigens could be concentrated in this
condition. Although these findings could not explain the
mechanism of serum elevation, they may support the thesis
that pathological conditions related to stagnation of
pancreatic juice play a significant role.
CA19-9
(+) n= 30
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(-) n = 40
MPD stenosis
or obstruction
(+) n= 18
(-) n = 49
(+) n= 15
Pseudocyst
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(+) n= 15
CBD stenosis
(-) n = 46
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Umi
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P< 0.05
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Figure 2 Bar graph demonstrates the median and intraquartile ranges of serum CA242 and CA19-9 levels for each pathological
condition. The statistical significance of the effect of each condition was assessed by use of the Mann-Whitney U-test.
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Figure 3 Summary of immunohistochemical analysis for CA242 and CAl9-9 in 12 chronic pancreatitis tissues. (a) The frequency
and intensity ofexpression in various levels of the duct systems and hyperplasia. (b) Localisation ofantigen expression in small and
large ducts.
Figure 4 Expression of each marker in centroacinar cells,
terminal ductules and small ducts. (a) CA242 staining; immuno-
reactivity is restricted to small ducts. (b) CA19-9 staining;
immunoreactivity (+ + intensity) is seen at various levels of
duct systems.
The mechanisms concerning the false serum elevation of
tumour markers in chronic pancreatitis have been analysed
by means of immunohistochemical study. Satomura et al.
(1991) reported that disturbed antigen polarity plays a
significant role in the elevation of serum CA19-9 levels. In
chronic pancreatitis tissues, cytoplasmic staining was
observed in addition to apical staining, whereas only apical
staining was seen in normal pancreatic tissues. The
correlation between the disturbed antigen polarity and
serum level was reported to be more prominent in pancreatic
cancer tissues (Satomura et al., 1991). However, a different
study demonstrated no such relationship in colorectal cancer
tissues for CEA and CAl9-9 (Tabuchi et al., 1988). In the
present study, both antigens were mainly expressed in the
apical surface of duct cells, indicating that the disturbed
antigen polarity may play a small part, if any, in the false
serum elevation of these antigens.
In conclusion, the elevation of serum CA242 levels in
patients with chronic pancreatitis is considered to be less
influenced by the pathological conditions related to stagna-
tion of pancreatic juice as compared with CAI9-9 because of
its low level of expression in ductal systems. These results
further support the idea that CA242 is different from the
established tumour marker sialyl Lewisa (CA19-9).
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